Close Menu

A discussion is going on over at the DrugMonkey blog on the materials and methods sections of papers. "This stupid failure to actually publish the real methodology (yes, including how many times the prep failed before you lucked onto the one that worked and really don't know why!) wastes my taxpayer dollars," he writes, adding that page restrictions are a "lame excuse" for not publishing the real methodology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.